Eikonoklastes is developing a first-in-class gene therapy that overexpresses caveolin-1 (a membrane lipid raft-scaffolding protein that is critical for neuromuscular signaling and function) for treatment of a pipeline of neurodegenerative diseases. Our lead indication is ALS and our FIH clinical trial in ALS patients is underway, which is designed to ascertain human efficacy potential relatively early in the trial. We are also nearing IND for Alzheimer's, frontotemporal dementia, and others.